
Opinion|Videos|July 12, 2024
ASCO 2024 Highlights: Long-Term Data and the Future of Combination Therapies in Melanoma
Dr Lipson provides insights surrounding combination therapies in melanoma management.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What is the value of long-term follow-up data in melanoma? How does this impact use of treatment regimens?
- How do you foresee the role of combination therapies evolving in the treatment of melanoma over the next few years?
Advertisement
Related to this article

Insmed’s once-daily TPIP prodrug shows sustained lung vasodilation in PAH and PH-ILD, improving walk distance, PALM outcomes, and quality of life.

An international eDelphi panel of 62 dermatologists agreed on a 2-step algorithm for tapering psoriasis biologics.

Real-world data from CHEST 2026 show ETI improved lung function and BMI in children with CF aged 6 to 11, with the most gains in F508del homozygotes.

Birth centers are unavailable in 10 states, and 39% of birth center births are self-pay, as licensing and Medicaid pay limit access, a report finds.

ASPEN links green sputum to neutrophils and exacerbations; brensocatib (DPP1) lowers purulence, while meta-analysis supports fewer flare-ups in bronchiectasis.

Narcolepsy and idiopathic hypersomnia can go undiagnosed for years, and Epworth and RU-SATED screening help clinicians spot true sleepiness sooner.

At CHEST 2026, 3 speakers explained why respiratory medications stay expensive, assessed what recent federal, state, and industry fixes have achieved, and urged clinicians to use their voices on behalf of patients.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Ryzumvi for Presbyopia, Expanding its Label
2
Patents, Rebates, and a Policy Patchwork Keep Inhalers Costly, Panelists Say
3
How Flatiron Health’s Network Chief Is Building the Future For (and With) Community Oncology Practices
4
CHEST: The Face of Lung Cancer Has Changed, but Screening, Care Have Gaps
5

